Stony Brook Heart Institute Evaluates First Dissolvable Stent
STONY BROOK, NY – Specialists at Stony Brook University Heart Institute have launched a clinical trial investigating the first cardiovascular stent that opens a heart vessel the same way as metallic stents but then dissolves away naturally. The new stent could prove to have benefits over standard metallic drug-eluting stents in relation to vessel blood flow and how much natural motion returns to the vessel after it dissolves. Coronary artery disease (CAD) is the leading cause of death for men and women in the United States.
For patients who do not require open heart surgery to open blocked blood vessels, inserting metallic drug-eluting stents is standard therapy. Stony Brook specialists will compare the efficacy and safety of Absorb™, a drug-eluting bioresorbable vascular scaffold (BVS) manufactured by Abbott, to standard metallic drug-eluting stents in two groups of patients. Absorb will only be used in patients whose condition enables them to elect for the dissolvable stent. The Principal Investigator leading the trial at Stony Brook is Luis Gruberg, MD.
“This type of coronary stent that ‘disappears’ is the latest technology to treat vessel blockages,” said Dr. Gruberg, Professor of Medicine, Division of Cardiovascular Medicine, and Director of Research, Interventional Cardiology, at Stony Brook University School of Medicine. “Unlike metallic stents that stay within the vessels permanently, this stent completely dissolves within about two years after implantation and may promote natural vessel motion to the treated tissue.” Continue>
Page | 1 2
Posted in: Specialties | November 18, 2014
Posted in: Specialties | October 9, 2013